Do analysts prefer ABP or AQB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 AquaBounty Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ABP or AQB more profitable?

Abpro's return on equity of 0.00% beat AquaBounty Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Abpro N/A N/A -344.76% AquaBounty Technologies N/A -147.07% -28.73%

Do analysts recommend ABP or SNGX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Soligenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ABP or SNGX more profitable?

Abpro's return on equity of 0.00% beat Soligenix's return on equity. Company Net Margins Return on Equity Return on Assets Abpro N/A N/A -344.76% Soligenix N/A -180.25% -107.46%

Do analysts recommend ABP or LABT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Lakewood-Amedex Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, ABP or LABT?

Lakewood-Amedex Biotherapeutics is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abpro N/A N/A -$7.23M -$4.23 N/A Lakewood-Amedex Biotherapeutics N/A N/A -$3.85M -$4.75 N/A

Is ABP or LABT more profitable?

Company Net Margins Return on Equity Return on Assets Abpro N/A N/A -344.76% Lakewood-Amedex Biotherapeutics N/A N/A N/A

Do analysts rate ABP or CLGN?

CollPlant Biotechnologies has a consensus price target of $120.00, suggesting a potential upside of 2,531.58%. Given CollPlant Biotechnologies' higher possible upside, analysts plainly believe CollPlant Biotechnologies is more favorable than Abpro. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 CollPlant Biotechnologies 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts rate LIMN or ABP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Liminatus Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has better earnings & valuation, LIMN or ABP?

Liminatus Pharma is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liminatus Pharma N/A N/A -$10.21M -$23.50 N/A Abpro N/A N/A -$7.23M -$4.23 N/A

Is LIMN or ABP more profitable?

Company Net Margins Return on Equity Return on Assets Liminatus Pharma N/A N/A -256.58% Abpro N/A N/A -344.76%

Abpro (ABP) Competitors

$0.52 0.00 (0.00%)

As of 09/18/2026

Compare

ABP vs. AQB, SNGX, LABT, CLGN, and LIMN

Should you buy Abpro stock or one of its competitors? Abpro's main competitors and comparable companies include AquaBounty Technologies (AQB), Soligenix (SNGX), Lakewood-Amedex Biotherapeutics (LABT), CollPlant Biotechnologies (CLGN), and Liminatus Pharma (LIMN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Abpro compare to AquaBounty Technologies?

Abpro (NASDAQ:ABP) and AquaBounty Technologies (NASDAQ:AQB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
AquaBounty Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Abpro has higher earnings, but lower revenue than AquaBounty Technologies. AquaBounty Technologies is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A
AquaBounty Technologies	$2.47M	2.38	-$18.49M	-$0.82	N/A

In the previous week, AquaBounty Technologies had 2 more articles in the media than Abpro. MarketBeat recorded 2 mentions for AquaBounty Technologies and 0 mentions for Abpro. AquaBounty Technologies' average media sentiment score of 0.59 beat Abpro's score of 0.00 indicating that AquaBounty Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Abpro	Neutral
AquaBounty Technologies	Positive

23.3% of Abpro shares are held by institutional investors. Comparatively, 8.9% of AquaBounty Technologies shares are held by institutional investors. 13.7% of Abpro shares are held by company insiders. Comparatively, 1.0% of AquaBounty Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Abpro's return on equity of 0.00% beat AquaBounty Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abpro	N/A	N/A	-344.76%
AquaBounty Technologies	N/A	-147.07%	-28.73%

Summary

Abpro beats AquaBounty Technologies on 6 of the 11 factors compared between the two stocks.

How does Abpro compare to Soligenix?

Abpro (NASDAQ:ABP) and Soligenix (NASDAQ:SNGX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Soligenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Abpro's return on equity of 0.00% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abpro	N/A	N/A	-344.76%
Soligenix	N/A	-180.25%	-107.46%

In the previous week, Soligenix had 1 more articles in the media than Abpro. MarketBeat recorded 1 mentions for Soligenix and 0 mentions for Abpro. Abpro's average media sentiment score of 0.00 equaled Soligenix'saverage media sentiment score.

Company	Overall Sentiment
Abpro	Neutral
Soligenix	Neutral

23.3% of Abpro shares are owned by institutional investors. Comparatively, 3.6% of Soligenix shares are owned by institutional investors. 13.7% of Abpro shares are owned by insiders. Comparatively, 1.9% of Soligenix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Abpro has higher earnings, but lower revenue than Soligenix. Soligenix is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A
Soligenix	$120K	45.70	-$11.08M	-$0.98	N/A

Summary

Abpro beats Soligenix on 6 of the 10 factors compared between the two stocks.

How does Abpro compare to Lakewood-Amedex Biotherapeutics?

Abpro (NASDAQ:ABP) and Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

Lakewood-Amedex Biotherapeutics is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A
Lakewood-Amedex Biotherapeutics	N/A	N/A	-$3.85M	-$4.75	N/A

Company	Net Margins	Return on Equity	Return on Assets
Abpro	N/A	N/A	-344.76%
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A

In the previous week, Lakewood-Amedex Biotherapeutics had 1 more articles in the media than Abpro. MarketBeat recorded 1 mentions for Lakewood-Amedex Biotherapeutics and 0 mentions for Abpro. Abpro's average media sentiment score of 0.00 equaled Lakewood-Amedex Biotherapeutics'average media sentiment score.

Company	Overall Sentiment
Abpro	Neutral
Lakewood-Amedex Biotherapeutics	Neutral

23.3% of Abpro shares are owned by institutional investors. 13.7% of Abpro shares are owned by company insiders. Comparatively, 5.4% of Lakewood-Amedex Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Lakewood-Amedex Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Abpro beats Lakewood-Amedex Biotherapeutics on 5 of the 8 factors compared between the two stocks.

How does Abpro compare to CollPlant Biotechnologies?

Abpro (NASDAQ:ABP) and CollPlant Biotechnologies (NASDAQ:CLGN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

23.3% of Abpro shares are owned by institutional investors. Comparatively, 21.7% of CollPlant Biotechnologies shares are owned by institutional investors. 13.7% of Abpro shares are owned by insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Abpro has higher earnings, but lower revenue than CollPlant Biotechnologies. CollPlant Biotechnologies is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A
CollPlant Biotechnologies	$389K	16.93	-$11.49M	-$14.50	N/A

Abpro has a net margin of 0.00% compared to CollPlant Biotechnologies' net margin of -683.68%. Abpro's return on equity of 0.00% beat CollPlant Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abpro	N/A	N/A	-344.76%
CollPlant Biotechnologies	-683.68%	-218.81%	-139.28%

CollPlant Biotechnologies has a consensus price target of $120.00, suggesting a potential upside of 2,531.58%. Given CollPlant Biotechnologies' higher possible upside, analysts plainly believe CollPlant Biotechnologies is more favorable than Abpro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, CollPlant Biotechnologies had 2 more articles in the media than Abpro. MarketBeat recorded 2 mentions for CollPlant Biotechnologies and 0 mentions for Abpro. Abpro's average media sentiment score of 0.00 equaled CollPlant Biotechnologies'average media sentiment score.

Company	Overall Sentiment
Abpro	Neutral
CollPlant Biotechnologies	Neutral

Summary

Abpro beats CollPlant Biotechnologies on 7 of the 11 factors compared between the two stocks.

How does Abpro compare to Liminatus Pharma?

Liminatus Pharma (NASDAQ:LIMN) and Abpro (NASDAQ:ABP) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

23.3% of Abpro shares are owned by institutional investors. 19.4% of Liminatus Pharma shares are owned by insiders. Comparatively, 13.7% of Abpro shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Company	Net Margins	Return on Equity	Return on Assets
Liminatus Pharma	N/A	N/A	-256.58%
Abpro	N/A	N/A	-344.76%

In the previous week, Liminatus Pharma's average media sentiment score of 0.00 equaled Abpro'saverage media sentiment score.

Company	Overall Sentiment
Liminatus Pharma	Neutral
Abpro	Neutral

Liminatus Pharma is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liminatus Pharma	N/A	N/A	-$10.21M	-$23.50	N/A
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A

Summary

Abpro beats Liminatus Pharma on 5 of the 7 factors compared between the two stocks.

Get Abpro News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABP vs. The Competition

Export

Metric	Abpro	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.42M	$3.92B	$7.25B	$13.14B
Dividend Yield	N/A	3.65%	2.57%	12.30%
P/E Ratio	-0.12	14.30	275.79	25.40
Price / Sales	N/A	1,415.50	695.58	114.44
Price / Cash	N/A	110.75	77.42	51.66
Price / Book	-0.06	15.45	10.46	6.33
Net Income	-$7.23M	-$22.86M	$3.49B	$358.33M
7 Day Performance	N/A	-1.21%	0.59%	1.12%
1 Month Performance	N/A	-4.42%	-2.01%	-2.67%
1 Year Performance	-92.87%	37.81%	18.09%	6.01%

Abpro Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABP Abpro	N/A	$0.52 flat	N/A	N/A	$1.42M	N/A	N/A	15
AQB AquaBounty Technologies	0.7108 of 5 stars	$1.11 +0.9%	N/A	-23.5%	$5.66M	$2.47M	N/A	100	News Coverage
SNGX Soligenix	0.3846 of 5 stars	$0.36 0.0%	N/A	-86.6%	$5.34M	$120K	N/A	20	News Coverage Positive News
LABT Lakewood-Amedex Biotherapeutics	0.1617 of 5 stars	$2.09 -3.7%	N/A	N/A	$5.14M	N/A	N/A	5	News Coverage
CLGN CollPlant Biotechnologies	1.5201 of 5 stars	$3.48 +2.4%	$120.00 +3,348.3%	-82.5%	$4.91M	$2.37M	N/A	70

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABP) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abpro (ABP) Competitors

ABP vs. AQB, SNGX, LABT, CLGN, and LIMN

How does Abpro compare to AquaBounty Technologies?

Summary

How does Abpro compare to Soligenix?

Summary

How does Abpro compare to Lakewood-Amedex Biotherapeutics?

Summary

How does Abpro compare to CollPlant Biotechnologies?

Summary

How does Abpro compare to Liminatus Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABP vs. The Competition

Abpro Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Abpro (ABP) Competitors

ABP vs. AQB, SNGX, LABT, CLGN, and LIMN

How does Abpro compare to AquaBounty Technologies?

Do analysts prefer ABP or AQB?

Which has stronger valuation and earnings, ABP or AQB?

Does the media refer more to ABP or AQB?

Do insiders & institutionals have more ownership in ABP or AQB?

Is ABP or AQB more profitable?

Summary

How does Abpro compare to Soligenix?

Do analysts recommend ABP or SNGX?

Is ABP or SNGX more profitable?

Does the media favor ABP or SNGX?

Do institutionals & insiders hold more shares of ABP or SNGX?

Which has stronger earnings & valuation, ABP or SNGX?

Summary

How does Abpro compare to Lakewood-Amedex Biotherapeutics?

Which has better valuation & earnings, ABP or LABT?

Is ABP or LABT more profitable?

Does the media prefer ABP or LABT?

Do insiders & institutionals hold more shares of ABP or LABT?

Do analysts recommend ABP or LABT?

Summary

How does Abpro compare to CollPlant Biotechnologies?

Do insiders and institutionals hold more shares of ABP or CLGN?

Which has higher earnings & valuation, ABP or CLGN?

Is ABP or CLGN more profitable?

Do analysts rate ABP or CLGN?

Does the media refer more to ABP or CLGN?

Summary

How does Abpro compare to Liminatus Pharma?

Do insiders & institutionals have more ownership in LIMN or ABP?

Do analysts rate LIMN or ABP?

Is LIMN or ABP more profitable?

Does the media favor LIMN or ABP?

Which has better earnings & valuation, LIMN or ABP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABP vs. The Competition

Abpro Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools